BeyondSpring Priced, Nasdaq: BYSI

Developing a cancer therapy to combat the loss of white blood cells.

Industry: Health Care

Latest Trade: $43.00 +1.20 (+2.9%)

First Day Return: -16.0%

Return from IPO: +109.0%

Industry: Health Care

We are a global clinical stage biopharmaceutical company focused on the development of innovative cancer therapies. We are advancing our lead asset, Plinabulin, into a Phase 2/3 clinical trial for the reduction of docetaxel chemotherapy-induced severe, grade 4 neutropenia, a Phase 2/3 clinical trial for the prevention of non-docetaxel chemotherapy-induced severe, grade 4 neutropenia, and a Phase 3 clinical trial as an anticancer agent in combination with docetaxel in advanced non-small cell lung cancer, or NSCLC. Plinabulin has also entered the first of a number of planned Phase 1/2 clinical trials to investigate its therapeutic potential in combination with the immuno-oncology agent nivolumab. In addition, we are developing three preclinical agents internally and up to six new agents a year for the next five years through our research collaborations.
more less
IPO News for BeyondSpring
more
IPO Data
IPO File Date 11/15/2016
Offer Price $20.00
Price Range $20.00 - $22.00
Offer Shares (mm) 0.2
Deal Size ($mm) $3
IPO Data
IPO Date 03/08/2017
Offer Price $20.00
Price Range $20.00 - $22.00
Offer Shares (mm) 0.2
Deal Size ($mm) $3
Underwriters
more
Company Data
Headquarters New York, NY
Founded 2014
Employees 25
Website www.beyondspringpharma.com